Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 211 of 211 entries
View as:

Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04137588 Org: User:
Start: 03/03/21 End: 06/01/22 Due: 06/01/23

Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT04622566 Org: User:
Start: 12/30/20 End: 12/30/23 Due: 12/30/24

To Identify KRAS Gene and Safe Margin in Association With Outcome in Colorectal Liver Metastases Following Ultrasound-guided Radiofrequency Ablation

Phase: N/A Priority: Normal
NCT ID: NCT04417010 Org: User:
Start: 06/01/20 End: 05/31/23 Due: 05/31/24

Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations

Phase: N/A Priority: Normal
NCT ID: NCT03454919 Org: User:
Start: 03/30/18 End: 06/30/20 Due: 06/30/21

Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal Lesions

Phase: N/A Priority: Normal
NCT ID: NCT04170257 Org: User:
Start: 10/18/19 End: 12/31/22 Due: 12/31/23

Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

Phase: N/A Priority: Normal
NCT ID: NCT05969184 Org: User:
Start: 12/25/21 End: 12/25/24 Due: 12/25/25

Clinical Application of Lutetium [177Lu]-Catalase in Tumor Radionuclide Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05985278 Org: User:
Start: 07/06/23 End: 06/15/26 Due: 06/15/27

18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03051555 Org: User:
Start: 03/01/17 End: 12/31/20 Due: 12/31/21

A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination with Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06869213 Org: User:
Start: 03/31/25 End: 12/31/27 Due: 12/31/28

Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT01167049 Org: User:
Start: 08/31/09 End: 12/31/13 Due: 12/31/14

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination with Chemotherapy for Organ Preservation in Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06869226 Org: User:
Start: 04/30/25 End: 12/31/29 Due: 12/31/30